Jason Prestinario, Particle Health
Jason Prestinario is CEO of Particle Health. The company is best known for its current…
Jason Prestinario, Particle Health
Jason Prestinario is CEO of Particle Health. The company is best known for its current lawsuit against Epic, but behind that there is a real company delivering a set of products as on ramp for clients wanting to access health data. Particle was cut off from access to Carequality & Epic a couple of years…
Why do U.S. physicians make so much money?
Let’s look at some data on mean annual physician income in the U.S. compared to other countries: U.S.: $458,100Canada: $194,700Netherlands: $185,700Sweden: $115,200 Why are U.S. physician incomes so much higher than other developed countries? Is it a good idea to try to drive down physician incomes? An NBER working paper by Buehler et al. (2026)…
How A Small Rural Hospital Is Using AI to Catch Heart Disease Sooner
At Wayne General Hospital in rural Mississippi, clinicians are using Eko Health’s AI-powered digital stethoscope to detect heart conditions earlier in patients with limited access to specialists. The post How A Small Rural Hospital Is Using AI to Catch Heart Disease Sooner appeared first on MedCity News.
AHIP CEO: “We Are Laser-Focused on Affordability”
Rising healthcare costs are a key focus for AHIP, whose CEO says the group is pushing reforms to boost competition and reduce administrative burden. The post AHIP CEO: “We Are Laser-Focused on Affordability” appeared first on MedCity News.
The Status of Abortion-related State Ballot Initiatives Since Dobbs
Last updated on March 24, 2026 Since the Supreme Court’s Dobbs decision, overturning Roe v. Wade, voters in 17 states have weighed in on ballot measures regarding abortion– some more than once. In November 2026, voters in Missouri, Nevada, and Virginia will weigh in on abortion measures that could change the legal status of abortion in their state. In addition, measures in Idaho and Nebraska are in the process of collecting signatures.
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition
Gilead Sciences is acquiring Ouro Medicines, a startup developing T cell engagers for a range of autoimmune diseases. Separately, Gilead is negotiating a deal with Galapagos to share in the development and potential commercialization of the Ouro drug. The post Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition appeared first…
Claims Denials and Appeals in ACA Marketplace Plans in 2024
This brief analyzes federal transparency data published by CMS on claims denials and appeals for Marketplace plan offered on HealthCare.gov in 2024, and finds insurers denied 19% of in-network claims. Consumers rarely appeal denied claims.
Virtual Specialty Care Has Time. Will We Use It Wisely?
The specialty access and capacity crisis demands more than incremental fixes. It requires expanding virtual access and fundamentally rethinking how specialty care can be delivered. The post Virtual Specialty Care Has Time. Will We Use It Wisely? appeared first on MedCity News.
AI Won’t Replace Clinical Trial Teams, But It Fixes the Bottlenecks That Keep Patients Out
We don’t have a shortage of willing patients — instead we have a shortage of scalable ways to identify and engage them responsibly. AI, used meaningfully offers a reliable path forward. The post AI Won’t Replace Clinical Trial Teams, But It Fixes the Bottlenecks That Keep Patients Out appeared first on MedCity News.
What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare & Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demonstration programs including the BALANCE Model, and potential impacts on beneficiaries and program budgets.
